| Segment Reporting [Table Text Block] |
| | | April 30, | | | April 30, | |
| | | 2026 | | | 2025 | |
| | | | | | | | | |
| Gross Margin | | $ | 2,551 | | | $ | 2,470 | |
| Segment operating expenses: | | | | | | | | |
| Clinical and regulatory | | | 644,157 | | | | 756,189 | |
| Research and development | | | 2,025,445 | | | | 3,456,312 | |
| Sales and marketing | | | 616,323 | | | | 350,167 | |
| Operations | | | 169,410 | | | | 173,604 | |
| General and administrative | | | 4,960,083 | | | | 3,618,769 | |
| Loss from operations | | | (8,412,867 | ) | | | (8,352,571 | ) |
| Interest expense | | | 753,041 | | | | 500,453 | |
| Other income | | | (24,033 | ) | | | (87,795 | ) |
| Total other expense | | | 729,008 | | | | 412,658 | |
| Net loss | | $ | (9,141,875 | ) | | $ | (8,765,229 | ) |
|